ArticleCell reports methods2021
A pan-cancer survey of cell line tumor similarity by feature-weighted molecular profiles.
Article in Cell reports methods, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- TRPM4 Expression as a Predictive Biomarker and a Mechanistic Driver of Acetalax Activity in Prostate Cancer: Preclinical Efficacy Studies.Molecular cancer therapeutics · 2026Article
- A platform of serially transplantable AML PDX models covering subgroups for which no cell lines exist.HemaSphere · 2026Article
- Establishment and characterization of NCC-GCTB16-C1: novel patient-derived cell line of giant cell tumor of bone.Human cell · 2026Article
- Convergence of machine learning and genomics for precision oncology.Nature reviews. Cancer · 2026Review
- CellMiner cross-database (CellMinerCDB) version 2.2 for explorations of patient-derived cancer cell line pharmacogenomics.Nucleic acids research · 2026Article
- Establishment and characterization of three canine ameloblastoma cell lines with genomic and transcriptomic profiles.PloS one · 2026Article
- Spatial proteomics of ovarian cancer precursors delineates early disease changes and drug targets.Molecular systems biology · 2026Article
- Learning Patient Similarity from Genomics for Precision Oncology.medRxiv : the preprint server for health sciences · 2025Article
- Uncovering the Understanding of the Concept of Patient Similarity in Cancer Research and Treatment: Scoping Review.Journal of medical Internet research · 2025Article
- Establishment of Coala: a novel 3D and 2D cancer cell line derived from colorectal cancer liver metastasis.Human cell · 2025Article
- Assessing individual head and neck squamous cell carcinoma patient response to therapy through integration of functional and genomic data.Scientific reports · 2025Article
- Computational models for pan-cancer classification based on multi-omics data.Frontiers in genetics · 2025Review
- Stem cell modeling of nervous system tumors.Disease models & mechanisms · 2024Review
- Characterization of tumor suppressors and oncogenes evaluated from TCGA cancers.American journal of clinical and experimental immunology · 2024Article
- Systematic transcriptional analysis of human cell lines for gene expression landscape and tumor representation.Nature communications · 2023Article
- Review
- Article
- Article
- CNpare: matching DNA copy number profiles.Bioinformatics (Oxford, England) · 2022Article
- Computational estimation of quality and clinical relevance of cancer cell lines.Molecular systems biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Patient-derived cell lines are often used in pre-clinical cancer research, but some cell lines are too different from tumors to be good models. Comparison of genomic and expression profiles can guide the choice of pre-clinical models, but typically not all features are equally relevant. We present TumorComparer, a computational method for comparing cellular profiles with higher weights on functional features of interest. In this pan-cancer application, we compare ∼600 cell lines and ∼8,000 tumor samples of 24 cancer types, using weights to emphasize known oncogenic alterations. We characterize the similarity of cell lines and tumors within and across cancers by using multiple datum types and rank cell lines by their inferred quality as representative models. Beyond the assessment of cell lines, the weighted similarity approach is adaptable to patient stratification in clinical trials and personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.